FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956111437> ?p ?o ?g. }

• W2956111437 abstract "Anaplastic lymphoma kinase (ALK), an oncogenic receptor tyrosine kinase, has emerged as a therapeutic target in various cancers, including lung cancer. Although several ALK inhibitors have gained regulatory approval, some of them do not cross the blood-brain barrier;1 furthermore, non-invasive indicators of target engagement or biomarkers predicting response to these agents in vivo are lacking. To overcome these limitations, fluorinated analogues of the ALK inhibitors crizotinib and alectinib (fluoroethyl crizotinib [FECr] and fluoroethyl alectinib [FEAl]) were synthesised and radiolabeled. We report the radiosynthesis and preliminary biological results on these compounds, fluoroethyl crizotinib (19F/18F-FECr) and fluoroethyl alectinib (19F/18F-FEAl). Briefly, 19F/18F-FECr and 19F/18F-FEAl were synthesized as previously reported.219F/18F-fluoroethyl tosylate was prepared, purified and coupled with crizotinib or alectinib. The products were purified by flash column chromatography to yield 19F/18F-FECr and 19F/18F-FEAl. Alternatively, precursor compounds were synthesized, directly fluorinated with 19F/18F-fluoride, and purified to yield 19F/18F-FECr and 19F/18F-FEAl. In vitro cytotoxicity assays were performed in lung cancer ALK-positive H2228 and ALK-negative H441 cells using non-radioactive compounds. In vivo biodistribution and PET/CT imaging studies were performed on tumor-free nude mice using 18F-labeled compounds. Chemically, the first method produced 18F-FECr in 20-24% yield (n=8), molar activity of 37 GBq/μmol, and >99% purity. The second method produced 18F-FECr and 18F-FEAl in 40% (n=6) and 20% yields, respectively. In in vitro cytotoxicity assays with ALK-positive H2228 cells, FECr showed an IC50 = 7.5 μM and FEAl an IC50 = 40 nM, similar to their cognate parental compound, confirming that the modification was not detrimental to drug potency. Positron emission tomographic (PET) imaging in tumor-free mice showed significant brain uptake of the 18F-labeled analogues at 10 min post-injection (6.5 %/ID/g, 18F-FECr; 8.2 %ID/g, 18F-FEAl). In conclusion, novel fluoroethyl-modified crizotinib and alectinib and their 18F-labeled analogues were synthesized with good yields, high purity, and high specific activity. PET and biodistribution results suggest that these fluorinated analogues may penetrate the blood-brain barrier and be potential targeted drugs for treatment of lung cancer that has metastasised to brain. References: 1. Kodama T, et al. Cancer Chemother Pharmacol 2014, 74, 1023-1028. 2. Perera et al. J. Labelled Com Radiopharm. 2016, 59 103-108. Citation Format: Mian M. Alauddin, Bhasker Radaram, Yi Rao, Ping Yang, David Piwnica-Worms. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling and preliminary biological studies on crizotinib and alectinib analogues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 10." @default.
• W2956111437 created "2019-07-12" @default.
• W2956111437 creator A5026528566 @default.
• W2956111437 creator A5027066179 @default.
• W2956111437 creator A5030842813 @default.
• W2956111437 creator A5051752608 @default.
• W2956111437 creator A5064151398 @default.
• W2956111437 date "2019-07-01" @default.
• W2956111437 modified "2023-09-30" @default.
• W2956111437 title "Abstract 10: Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling and preliminary biological studies on crizotinib and alectinib analogues" @default.
• W2956111437 doi "https://doi.org/10.1158/1538-7445.sabcs18-10" @default.
• W2956111437 hasPublicationYear "2019" @default.
• W2956111437 type Work @default.
• W2956111437 sameAs 2956111437 @default.
• W2956111437 citedByCount "0" @default.
• W2956111437 crossrefType "proceedings-article" @default.
• W2956111437 hasAuthorship W2956111437A5026528566 @default.
• W2956111437 hasAuthorship W2956111437A5027066179 @default.
• W2956111437 hasAuthorship W2956111437A5030842813 @default.
• W2956111437 hasAuthorship W2956111437A5051752608 @default.
• W2956111437 hasAuthorship W2956111437A5064151398 @default.
• W2956111437 hasConcept C117643217 @default.
• W2956111437 hasConcept C126322002 @default.
• W2956111437 hasConcept C150903083 @default.
• W2956111437 hasConcept C185592680 @default.
• W2956111437 hasConcept C202751555 @default.
• W2956111437 hasConcept C207001950 @default.
• W2956111437 hasConcept C2776232967 @default.
• W2956111437 hasConcept C2776256026 @default.
• W2956111437 hasConcept C2776970183 @default.
• W2956111437 hasConcept C2777807558 @default.
• W2956111437 hasConcept C2779220645 @default.
• W2956111437 hasConcept C2779422266 @default.
• W2956111437 hasConcept C2779750558 @default.
• W2956111437 hasConcept C502942594 @default.
• W2956111437 hasConcept C55493867 @default.
• W2956111437 hasConcept C71924100 @default.
• W2956111437 hasConcept C86803240 @default.
• W2956111437 hasConcept C98274493 @default.
• W2956111437 hasConceptScore W2956111437C117643217 @default.
• W2956111437 hasConceptScore W2956111437C126322002 @default.
• W2956111437 hasConceptScore W2956111437C150903083 @default.
• W2956111437 hasConceptScore W2956111437C185592680 @default.
• W2956111437 hasConceptScore W2956111437C202751555 @default.
• W2956111437 hasConceptScore W2956111437C207001950 @default.
• W2956111437 hasConceptScore W2956111437C2776232967 @default.
• W2956111437 hasConceptScore W2956111437C2776256026 @default.
• W2956111437 hasConceptScore W2956111437C2776970183 @default.
• W2956111437 hasConceptScore W2956111437C2777807558 @default.
• W2956111437 hasConceptScore W2956111437C2779220645 @default.
• W2956111437 hasConceptScore W2956111437C2779422266 @default.
• W2956111437 hasConceptScore W2956111437C2779750558 @default.
• W2956111437 hasConceptScore W2956111437C502942594 @default.
• W2956111437 hasConceptScore W2956111437C55493867 @default.
• W2956111437 hasConceptScore W2956111437C71924100 @default.
• W2956111437 hasConceptScore W2956111437C86803240 @default.
• W2956111437 hasConceptScore W2956111437C98274493 @default.
• W2956111437 hasLocation W29561114371 @default.
• W2956111437 hasOpenAccess W2956111437 @default.
• W2956111437 hasPrimaryLocation W29561114371 @default.
• W2956111437 hasRelatedWork W2000768445 @default.
• W2956111437 hasRelatedWork W2028406996 @default.
• W2956111437 hasRelatedWork W2042183644 @default.
• W2956111437 hasRelatedWork W2064801613 @default.
• W2956111437 hasRelatedWork W2069734284 @default.
• W2956111437 hasRelatedWork W2324907818 @default.
• W2956111437 hasRelatedWork W2411417130 @default.
• W2956111437 hasRelatedWork W2412662819 @default.
• W2956111437 hasRelatedWork W2606025347 @default.
• W2956111437 hasRelatedWork W2691745207 @default.
• W2956111437 hasRelatedWork W2742326943 @default.
• W2956111437 hasRelatedWork W2753276548 @default.
• W2956111437 hasRelatedWork W2975675601 @default.
• W2956111437 hasRelatedWork W2982331146 @default.
• W2956111437 hasRelatedWork W3013726674 @default.
• W2956111437 hasRelatedWork W3037524973 @default.
• W2956111437 hasRelatedWork W3046093120 @default.
• W2956111437 hasRelatedWork W3107475507 @default.
• W2956111437 hasRelatedWork W3168529792 @default.
• W2956111437 hasRelatedWork W3190447870 @default.
• W2956111437 isParatext "false" @default.
• W2956111437 isRetracted "false" @default.
• W2956111437 magId "2956111437" @default.
• W2956111437 workType "article" @default.